Novanta Inc. (NOVT) is a global supplier of precision medicine, precision manufacturing, medical solutions, and robotics and automation technology to medical, life science, and advanced industrial equipment makers. Analyst coverage of the stock is relatively thin, with only a small number of firms publishing price targets.
The verified targets reviewed converge tightly around $194 to $195. Robert W. Baird raised its target to $194 from $180 and maintained an Outperform rating in August 2026, while a second firm carried a $195 target, producing a calculated mean of roughly $194.50 — rounded to $195 for this analysis. William Blair also maintains a Buy rating without a published target in recent data. Because the range is so narrow, the figures should be read as a limited but broadly constructive Street view rather than a broad-based consensus.
Following its third-quarter 2026 report, the stock closed near $146, up sharply on the session as revenue beat expectations. From that level, reaching $195 implies about 33% upside, which is a substantial move by any standard and would require both sustained execution and multiple expansion.
Novanta's Q3 2026 results were strong on the top line: revenue rose 23.1% year over year to $305 million, exceeding consensus, and non-GAAP EPS of $1.05 beat estimates. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached $80.3 million, a 26.3% margin. Bookings climbed 29% and backlog reached $543 million, providing near-term visibility. However, management's fourth-quarter adjusted EPS guidance of $0.91–$0.96 came in below consensus, and full-year adjusted EPS guidance was trimmed to a $3.69 midpoint.
The stock experienced a pronounced earnings-day move, trading intraday between roughly $138 and $147 before settling near $146, with after-hours activity pulling back toward the low $140s. The $150 area stands out as a psychological resistance level, while the earnings-day gap and the upper-$130s zone represent nearby reference points. Broader technical context is limited by thin data, so these levels should be treated as general zones rather than precise, verified support or resistance.
Analyst price targets generally reflect a research horizon of about 12 months, though individual assumptions vary. Key items to watch include fourth-quarter and full-year 2026 results against the lowered EPS guidance, continued booking and backlog trends, progress on Riverpoint Medical integration and synergies, any further analyst revisions, and the company's presentation at the Baird 2026 Global Industrial Conference. Macroeconomic conditions affecting medical device and industrial automation demand also matter.
AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and identify changing trends more efficiently than manual screening allows. For those tracking NOVT, combining this tool with fundamental research can help flag momentum shifts as they develop.
Reaching $195 would require Novanta to advance about 33% from recent levels — a substantial move that the current analyst targets, clustered near $194–$195, suggest the Street views as achievable over a typical research horizon. The bullish case rests on accelerating revenue, record bookings, a large strategic acquisition, and margin improvement. The bearish case points to trimmed EPS guidance, weak GAAP profitability, integration risk, and a demanding valuation. With coverage concentrated and guidance mixed, investors should watch execution and earnings revisions closely before drawing conclusions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, NOVT has been loosely correlated with ST. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if NOVT jumps, then ST could also see price increases.
| Ticker / NAME | Correlation To NOVT | 1D Price Change % | ||
|---|---|---|---|---|
| NOVT | 100% | -15.26% | ||
| ST - NOVT | 52% Loosely correlated | -0.40% | ||
| VPG - NOVT | 51% Loosely correlated | +1.29% | ||
| BKSY - NOVT | 40% Loosely correlated | -0.25% | ||
| CGNX - NOVT | 39% Loosely correlated | +0.91% | ||
| ITRN - NOVT | 39% Loosely correlated | -4.21% | ||
More | ||||